Immunogenic Epitopes for Fibroblast Growth Factor-5 (FGF-5) Presented by HLA-A3 and HLA-A2
Description of Invention:
Approximately 30,000 patients are diagnosed with renal cell carcinoma (RCC) each year in the United States, and an estimated 12,000 patients die of this disease. Most patients are diagnosed with advanced local disease or metastatic disease. Current therapies include removal of the kidney (nephrectomy) or high dose immunotherapy with IL-2, which has been able to achieve success in only part (15-20%) of the patient population. Even with a successful nephrectomy, it is likely that patients with advanced local diseases will develop metastases. Therefore, new methods are needed to improve on IL-2 therapy and expand the curative potential of therapies for patients with RCC.
The present invention discloses peptides for use in immunotherapy of tumors. The peptides, both an HLA-A2 and an HLA-A3 epitope, are derived from the amino acid sequence of an RCC-associated antigen, fibroblast growth factor-5 (FGF-5). Plans are underway to investigate both peptides in clinical trials of peptide vaccination in patients with advanced renal cancer. In addition, FGF-5 also appears to be over-expressed in other common adenocarcinomas such as breast, prostate and bladder cancer and very few antigens suitable for vaccine therapies exist for those cancers.
Inventors:
James C. Yang et al. (NCI)
Patent Status:
DHHS Reference No. E-031-2003/1 --
U.S. Patent Application No. 11/134,703 filed 19 May 2005
Related Technologies: DHHS Reference No. E-031-2003/0 --
U.S. Provisional Application No. 60/427,920 filed 19 Nov 2002
PCT Application No. PCT/US03/37065 filed 19 Nov 2003, which published as WO 2004/045555 on 03 Jun 2004
Licensing Status: This technology is no longer available for licensing
Portfolios: Cancer
Cancer -Therapeutics-Vaccines Cancer -Therapeutics
For Additional Information Please Contact: Michelle A. Booden Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)451-7337
Email: boodenm@mail.nih.gov
Fax: (301) 402-0220
